NDAORALTABLET
Approved
Jul 2017
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
5/8 — Partial
ZYPITAMAG (pitavastatin magnesium) by Medicure is hydroxymethylglutaryl-coa reductase inhibitors [moa]. Approved for hmg-coa reductase inhibitor [epc]. First approved in 2017.
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYPITAMAG (pitavastatin magnesium) is an oral HMG-CoA reductase inhibitor (statin) approved in 2017 for the treatment of hypercholesterolemia. It works by inhibiting HMG-CoA reductase, a key enzyme in cholesterol synthesis, thereby reducing LDL cholesterol and triglycerides. The magnesium formulation enhances bioavailability and tolerability compared to the base compound.
$0.004BPart D
Peak4.4 years to LOEProduct is in peak revenue phase with modest Part D uptake (8,034 claims in 2023), suggesting stable but modest market penetration in a competitive therapeutic class.
Mechanism of Action
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Class:
HMG-CoA Reductase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on ZYPITAMAG at Medicure? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.